You are here

New Fluticasone Furoate/Vilanterol Combo Drug Submitted for FDA Review

GSK and Theravance seek an indication for FF/VI (100/25 mcg) for the long-term once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema, and to reduce exacerbations of COPD in patients with a history of exacerbations.

GSK and Theravance are reviewing the strategy for a future U.S. filing for asthma.

FF/VI is one of several respiratory medicines being developed by GSK. Other potential products include the investigational LAMA/LABA combination umeclidinium bromide (UMEC)/VI, VI monotherapy, and MABA (GSK961081), all developed in collaboration with Theravance. GSK is also developing FF monotherapy, UMEC monotherapy, and an anti-IL5 monoclonal antibody (mepolizumab).

Read the news release from GlaxoSmithKline.

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial
Evenity Increases New Bone Formation, Lowers Vertebral Fracture Potential